The accumulation of versican in the nodules of benign prostatic hyperplasia

Prostate

Volumn 69, Issue 2, 2009, Pages 149-158

  True, Lawrence D ^a   Hawley, Sarah ^b   Norwood, Thomas H ^a   Braun, Kathleen R ^c   Evanko, Stephen P ^c   Chan, Christina K ^c   Lebaron, Richard C ^d   Wight, Thomas N ^c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Canary Foundation   (United States)

^c BENAROYA RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

Author keywords

Extracellular matrix; Prostate hyperplasia; Proteoglycans; Versican

Indexed keywords

GENE PRODUCT; MESSENGER RNA; VERSICAN; COMPLEMENTARY DNA; GLYCOSAMINOGLYCAN; RNA; UNCLASSIFIED DRUG; VCAN PROTEIN, HUMAN;

ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; NORTHERN BLOTTING; PARENCHYMA; PRIORITY JOURNAL; PROSTATE; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STEADY STATE; WESTERN BLOTTING; EXON; GENETIC TRANSCRIPTION; GENETICS; HISTOLOGY; ISOLATION AND PURIFICATION; METABOLISM; ORGAN SIZE; PATHOLOGY; PROSTATECTOMY;

DNA, COMPLEMENTARY; EXONS; GLYCOSAMINOGLYCANS; HUMANS; MALE; ORGAN SIZE; PROSTATE; PROSTATECTOMY; PROSTATIC HYPERPLASIA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; TRANSCRIPTION, GENETIC; VERSICANS;

EID: 58849142551     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20861     Document Type: Article

References (49)

1. Coffey DS, Walsh PC. Clinical and experimental studies of benign prostatic hyperplasia. Urol Clin North Am 1990;17(3):461-475.
2. Oesterling JE. The origin and development of benign prostatic hyperplasia. An age-dependent process. J Androl 1991;12(6):348-355.
3. LaVecchiaC, LeviF, Lucchini F. Mortality from benign prostatic hyperplasia: Worldwide trends. 1950-1992. J Epidemiol Community Health 1995;49(4):379-384.
4. Rohr HP, Bartsch G. Human benign prostatic hyperplasia: A stromal disease? New perspectives by quantitative morphology. Urology 1980;16(6):625-633.
5. McNeal J. Pathology of benign prostatic hyperplasia. Insight into etiology. Urol Clin North Am 1990;17(3):477-486.
6. Bierhoff E, Vogel J, Benz M, Giefer T, Wernert N, Pfeifer U. Stromal nodules in benign prostatic hyperplasia. Eur Urol 1996;29(3):345-354.
7. Cunha GR, Fujii H, Neubauer BL, Shannon JM, Sawyer L, Reese BA. Epithelial-mesenchymal interactions in prostatic development. I. morphological observations of prostatic induction by urogenital sinus mesenchyme in epithelium of the adult rodent urinary bladder. J Cell Biol 1983;96(6):1662-1670.
8. Iida S, Suzuki K, Matsuoka K, Takazono I, Shimada A, Inoue M, Yahara J, Noda S. Analysis of glycosaminoglycans in human prostate by high-performance liquid chromatography. Br J Urol 1997;79(5):763-769.
9. De Klerk DP, Lee DV, Human HJ. Glycosaminoglycans of human prostatic cancer. J Urol 1984;131(5):1008-1012.
10. Terry DE, Clark AF. Glycosaminoglycans in the three lobes of the rat prostate following castration and testosterone treatment. Biochem Cell Biol 1996;74(5):653-658.
11. Terry DE, Clark AF. Influence of testosterone on chondroitin sulphate proteoglycan in the rat prostate. Biochem Cell Biol 1996;74(5):645-651.
12. Goulas A, Hatzichristou DG, Karakiulakis G, Mirtsou-Fidani V, Kalinderis A, Papakonstantinou E. Benign hyperplasia of the human prostate is associated with tissue enrichment in chondroitin sulphate of wide size distribution. Prostate 2000;44(2):104-110.
13. Margolis RU, Margolis RK. Aggrecan-versican-neurocan family proteoglycans. Methods Enzymol 1994;245:105-126.
14. Bode-Lesniewska B, Dours-Zimmermann MT, Odermatt BF, Briner J, Heitz PU, Zimmermann DR. Distribution of the large aggregating proteoglycan versican in adult human tissues. J Histochem Cytochem 1996;44(4):303-312.
15. Henderson DJ, Copp AJ. Versican expression is associated with chamber specification, septation, and valvulogenesis in the developing mouse heart. Circ Res 1998;83(5):523-532.
16. Mjaatvedt CH, Yamamura H, Capehart AA, Turner D, Mark-wald RR. The Cspg2 gene, disrupted in the hdf mutant, is required for right cardiac chamber and endocardial cushion formation. Dev Biol 1998;202(1):56-66.
17. Isogai Z, Shinomura T, Yamakawa N, Takeuchi J, Tsuji T, Heinegard D, Kimata K. 2B1 antigen characteristicallyexpressed on extracellular matrices of human malignant tumors is a large chondroitin sulfate proteoglycan, PG-M/versican. Cancer Res 1996;56(17):3902-3908.
18. Paulus W, Baur I, Dours-Zimmermann MT, Zimmermann DR. Differential expression of versican isoforms in brain tumors. J Neuropathol Exp Neurol 1996;55(5):528-533.
19. Nara Y, Kato Y, Torii Y, Tsuji Y, Nakagaki S, Goto S, Isobe H, Nakashima N, Takeuchi J. Immunohistochemical localization of extracellular matrix components in human breast tumours with special reference to PG-M/versican. Histochem J 1997;29(1):21-30.
20. Brown LF, Guidi AJ, Schnitt SJ, Van De Water L, Iruela-Arispe ML, Yeo TK, Tognazzi K, Dvorak HF. Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast. Clin Cancer Res 1999;5(5):1041-1056.
21. Touab M, Villena J, Barranco C, Arumi-Uria M, Bassols A. Versican is differentially expressed in human melanoma and may play a role in tumor development. Am J Pathol 2002;160(2):549-557.
22. Ricciardelli C, Mayne K, Sykes PJ, Raymond WA, McCaul K, Marshall VR, Tilley WD, Skinner JM, Horsfall DJ. Elevated stromal chondroitin sulfate glycosaminoglycan predicts progression in early-stage prostate cancer. Clin Cancer Res 1997;3(6):983-992.
23. Walden PD, Lefkowitz GK, Ficazzola M, Gitlin J, Lepor H. Identification of genes associated with stromal hyperplasia and glandular atrophy of the prostate by mRNA differential display. Exp Cell Res 1998;245(1):19-26.
24. Cross NA, Chandrasekaran S, Jokonya N, Fowles A, Hamdy FC, Buttle DJ, Eaton CL. The expression and regulation of ADAMTS-1, -4, -5, -9, and -15, and TIMP-3 by TGFbeta 1 in prostate cells: Relevance to the accumulation of versican. Prostate 2005; 63(3):269-275.
25. du Cros DL, LeBaron RG, Couchman JR. Association of versican with dermal matrices and its potential role in hair follicle development and cycling. J Invest Dermatol 1995;105(3):426-431.
26. Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: A laboratory manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory. 1998.
27. Tricarico C, Pinzani P, Bianchi S, Paglierani M, Distante V, Pazzagli M, Bustin SA, Orlando C. Quantitative real-time reverse transcription polymerase chain reaction: Normalization to rRNA or single housekeeping genes is inappropriate for human tissue biopsies. Anal Biochem 2002;309(2):293-300.
28. Yao LY, Moody C, Schönherr E, Wight TN, Sandell LJ. Identification of the proteoglycan versican in aorta and smooth muscle cells by DNA sequence analysis, in situ hybridization and immunohistochemistry. Matrix Biol 1994;14:213-225.
29. Lemire JM, Potter-Perigo S, Hall KL, Wight TN, Schwartz SM. Distinct rat aortic smooth muscle cells differ in versican/PG-M expression. Arterioscler Thromb Vasc Biol 1996;16:821-829.
30. Lemire JM, Braun KR, Maurel P, Kaplan ED, Schwartz SM, Wight TN. Versican/PG-M isoforms in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 1999;19:1630-1639.
31. Zimmermann DR, Dours-Zimmermann MT, Schubert M, Bruckner-Tuderman L. Versican is expressed in the proliferating zone in the epidermis and in association with the elastic network in the dermis. J Cell Biol 1994;124:817-825.
32. Perissinotto D, Iacopetti P, Bellina I, Doliana R, Colombatti A, Pettway Z, Bronner-Fraser M, Shinomura T, Kimata K, Morgelin M, Lofberg J, Perris R. Avian neural crest cell migration is diversely regulated by the two major hyaluronan-binding proteoglycans PG-M/versican and aggrecan. Development 2000;127(13):2823-2842.
33. Sandy JD, Westling J, Kenagy RD, Iruela-Arispe ML, Verscharen C, Rodriguez-Mazaneque JC, Zimmermann DR, Lemire JM, Fischer JW, Wight TN, Clowes AW. Versican V1 proteolysis in human aorta in vivo occurs at the Glu441-Ala442 bond, a site that is cleaved by recombinant ADAMTS-1 and ADAMTS-4. J Biol Chem 2001;276(16):13372-13378.
34. Kenagy RD, Fischer JW, Davies MG, Berceli SA, Hawkins SM, Wight TN, Clowes AW. Increased plasmin and serine proteinase activity during flow-induced intimal atrophy in baboon PTFE grafts. Arterioscler Thromb Vasc Biol 2002;22(3):400-404.
35. Schönherr E, Järveläinen HT, Sandell LJ, Wight TN. Effects of platelet-derived growth factor and transforming growth factor-beta 1 on the synthesis of a large versican-like chondroitin sulfate proteoglycan by arterial smooth muscle cells. J Biol Chem 1991;266:17640-17647.
36. Evanko SP, Angello JC, Wight TN. Formation of hyaluronan and versican-rich pericellular matrix is required for proliferation and migration of vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 1999;19:1004-1013.
37. Wu Y, Zhang Y, Cao L, Chen L, Lee V, Zheng PS, Kiani C, Adams ME, Ang LC, Paiwand F, Yang BB. Identification of the motif in versican G3 domain that plays a dominant-negative effect on astrocytoma cell proliferation through inhibiting versican secretion and binding. J Biol Chem 2001;276(17):14178-14186.
38. Zhang Y, Cao L, Yang BL, Yang BB. The G3 domain of versican enhances cell proliferation via epidermial growth factor-like motifs. J Biol Chem 1998;273(33):21342-21351.
39. Zhang Y, Cao L, Kiani CG, Yang BL, Yang BB. The G3 domain of versican inhibits mesenchymal chondrogenesis via the epidermal growth factor-like motifs. J Biol Chem 1998;273(49):33054-33063.
40. Sakko AJ, Ricciardelli C, Mayne K, Tilley WD, Lebaron RG, Horsfall DJ. Versican accumulation in human prostatic fibroblast cultures is enhanced by prostate cancer cell-derived transforming growth factor beta1. Cancer Res 2001;61(3):926-930.
41. Luo J, Dunn T, Ewing C, Sauvageot J, Chen Y, Trent J, Isaacs W. Gene expression signature of benign prostatic hyperplasia revealed by cDNA microarray analysis. Prostate 2002;51(3):189-200.
42. Deering RE, Bigler SA, King J, Choongkittaworn M, Aramburu E, Brawer MK. Morphometric quantitation of stroma in human benign prostatic hyperplasia. Urology 1994;44(1):64-70.
43. Peehl DM. Cellular biology of prostatic growth factors. Prostate Suppl 1996;6:74-78.
44. Isaacs JT, Coffey DS. Etiology and disease process of benign prostatic hyperplasia. Prostate Suppl 1989;2:33-50.
45. McNeal JE. Origin and evolution of benign prostatic enlargement. Invest Urol 1978;15(4):340-345.
46. Norwood TH, Gray M. The role of DNA damage in cellular aging: Is it time for a reassessment? Exp Gerontol 1996;31(1-2):61-68.
47. Campisi J. From cells to organisms: Can we learn about aging from cells in culture? Exp Gerontol 2001;36(4-6):607-618.
48. GrayM, Norwood TH. Cellular aging in vitro. Rev Clin Gerontol 1995;5:369-381.
49. Krtolica A, Parrinello S, Lockett S, Desprez PY, Campisi J. Senescent fibroblasts promote epithelial cell growth and tumori-genesis: A link between cancer and aging. Proc Natl Acad Sci USA 2001;98(21):12072-12077.